Guardant Health, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

GH$155.35-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Deficit

(in thousands, except share data)

	Three Months Ended September 30, 2026
Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders’ Deficit
Shares · Amount
Balance as of July 1, 2026	133,612,678	$1	$3,009,424	$(5,563)	$(3,226,729)	$(222,867)
Issuance of common stock upon exercise of stock options	381,803	—	18,290	—	—	18,290
Vesting of restricted stock units	725,393	—	—	—	—	—
Employee taxes paid related to net share settlement of restricted stock units	—	—	(9,828)	—	—	(9,828)
Stock-based compensation	—	—	62,435	—	—	62,435
Other comprehensive income	—	—	—	430	—	430
Net loss	—	—	—	—	(124,362)	(124,362)
Balance as of September 30, 2026	134,719,874	$1	$3,080,321	$(5,133)	$(3,351,091)	$(275,902)

	Three Months Ended September 30, 2025
Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders’ Deficit
Shares · Amount · Treasury Stock
Balance as of July 1, 2025	124,477,904	$1	$(45,010)	$2,516,550	$(3,723)	$(2,773,293)	$(305,475)
Issuance of common stock upon exercise of stock options	117,508	—	—	3,721	—	—	3,721
Vesting of restricted stock units	410,303	—	—	—	—	—	—
Employee taxes paid related to net share settlement of restricted stock units	—	—	—	(2,265)	—	—	(2,265)
Stock-based compensation	—	—	—	42,808	—	—	42,808
Other comprehensive loss	—	—	—	—	(537)	—	(537)
Net loss	—	—	—	—	—	(92,725)	(92,725)
Balance as of September 30, 2025	125,005,715	$1	$(45,010)	$2,560,814	$(4,260)	$(2,866,018)	$(354,473)

	Nine Months Ended September 30, 2026
Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders’ Deficit
Shares · Amount
Balance as of January 1, 2026	130,635,301	$1	$2,900,056	$(4,852)	$(2,994,512)	$(99,307)
Issuance of common stock upon exercise of stock options	1,198,834	—	40,932	—	—	40,932
Vesting of restricted stock units	2,759,389	—	—	—	—	—
Common stock issued under employee stock purchase plan	126,350	—	10,362	—	—	10,362
Employee taxes paid related to net share settlement of restricted stock units	—	—	(38,797)	—	—	(38,797)
Stock-based compensation	—	—	167,768	—	—	167,768
Other comprehensive loss	—	—	—	(281)	—	(281)
Net loss	—	—	—	—	(356,579)	(356,579)
Balance as of September 30, 2026	134,719,874	$1	$3,080,321	$(5,133)	$(3,351,091)	$(275,902)

	Nine Months Ended September 30, 2025
Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders’ Deficit
Shares · Amount · Treasury Stock
Balance as of January 1, 2025	123,994,006	$1	$—	$2,443,788	$(5,201)	$(2,578,235)	$(139,647)
Issuance of common stock upon exercise of stock options	220,541	—	—	6,046	—	—	6,046
Vesting of restricted stock units	1,457,132	—	—	—	—	—	—
Common stock issued under employee stock purchase plan	310,387	—	—	7,680	—	—	7,680
Employee taxes paid related to net share settlement of restricted stock units	—	—	—	(25,183)	—	—	(25,183)
Stock-based compensation	—	—	—	123,027	—	—	123,027
Repurchase of stock	(976,351)	—	(45,010)	—	—	—	(45,010)
Unwinding of convertible note hedges	—	—	—	5,456	—	—	5,456
Other comprehensive income	—	—	—	—	941	—	941
Net loss	—	—	—	—	—	(287,783)	(287,783)
Balance as of September 30, 2025	125,005,715	$1	$(45,010)	$2,560,814	$(4,260)	$(2,866,018)	$(354,473)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.